[{"from": "human", "value": "What can you tell me about this molecule? [C][C][C][=Branch1][C][=O][O][C][C][=Branch1][C][=O][C@][Branch2][Ring2][=N][C@H1][Branch2][Ring2][Branch2][C][C@@H1][C@@][Ring1][Branch1][Branch2][Ring1][#C][C][C@@H1][Branch2][Ring1][=Branch2][C@][Branch2][Ring1][Ring2][C@H1][Ring1][=Branch1][C][C][C][=C][C][=Branch1][C][=O][C][=C][C@@][Ring1][#Branch1][Ring1][O][C][Cl][O][C][C][O][C][=Branch1][C][=O][C][C]"}, {"from": "gpt", "value": "The molecule is a second-generation synthetic corticosteroid and diester of beclomethasone, which is structurally similar to [dexamethasone]. It is a prodrug of an active metabolite beclomethasone 17-monopropionate (17-BMP) which acts on the glucocorticoid receptor to mediates its therapeutic action. Beclomethasone dipropionate itself posesses weak glucocorticoid receptor binding affinity and is rapidly converted into 17-BMP upon administration. Formulations for oral inhalation, intranasal, and topical use are available for beclomethasone dipropionate. Beclomethasone dipropionate became first available in a pressurized metered-dose inhaler in 1972 and later in a dry powder inhaler and an aqueous nasal spray. Due to its anti-inflammatory, antipruritic, and anti-allergy properties, beclomethasone dipropionate is used in various inflammatory conditions, such as asthma, allergic rhinitis, and dermatoses to reduce symptoms. When inhaled, it is proposed that beclomethasone dipropionate remains active locally in the lung without causing significant side effects associated with systemic corticosteroids. Compared to earlier corticosteroids such as [dexamethasone] and [prednisolone], beclomethasone dipropionate is reported to be less irritating to the nasal mucosa with a longer duration of action when administered intranasally."}]